Glaukos Corporation (GKOS) Tops Q2 EPS by 1c; Offers FY23 Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. FND
9. DASH
10. GILD

Go back to Glaukos Corporation (GKOS) Tops Q2 EPS by 1c; Offers FY23 Revenue Guidance

Glaukos Announces Second Quarter 2023 Financial Results

August 2, 2023 4:05 PM EDT

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2023. Key highlights include:

Net sales of $80.4 million in Q2 2023 increased 11% year-over-year. Glaucoma net sales of $61.9 million in Q2 2023 increased 10% year-over-year. Corneal Health net sales of $18.5 million in Q2 2023 increased 11% year-over-year. Gross margin of approximately 75% and non-GAAP gross margin of approximately 82% in Q2 2023. Raised 2023 net sales... More